CATX logo

CATXPerspective Therapeutics Inc

$2.99
$0.10
(3.30%)
Today
Closed $2.93
$0.06
(2.05%)
After Hours
Updated: 07:43 PM EDT
Reported EarningsMay 11
Mkt Cap$345.56M
Vol1.26M
News
all
press releases
4D Molecular Therapeutics, Inc. (FDMT) Reports Q1 Loss, Lags Revenue Estimates
4D Molecular Therapeutics (FDMT) delivered earnings and revenue surprises of -4.12% and -19.07%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
News Placeholder
More News
News Placeholder
New Treatment Modalities Are Reaching Cancers That Resisted Everything Else
New Treatment Modalities Are Reaching Cancers That Resisted Everything Else New Treatment Modalities Are Reaching Cancers That Resisted Everything Else PR Newswire VANCOUVER, BC, Feb. 17, 2026 Issued...
PR Newswire
News Placeholder
$668B Oncology Surge: 5 Platforms Cracking the Code on GI Tumors
$668B Oncology Surge: 5 Platforms Cracking the Code on GI Tumors $668B Oncology Surge: 5 Platforms Cracking the Code on GI Tumors PR Newswire VANCOUVER, BC, Jan. 30, 2026 Issued on behalf of...
PR Newswire
News Placeholder
Stevanato Group (STVN) Q3 Earnings and Revenues Surpass Estimates
Stevanato (STVN) delivered earnings and revenue surprises of +14.29% and +5.54%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks
News Placeholder
Rigel Pharmaceuticals (RIGL) Tops Q3 Earnings and Revenue Estimates
Rigel (RIGL) delivered earnings and revenue surprises of +56.99% and +12.80%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks
News Placeholder
Ionis Pharmaceuticals (IONS) Reports Q3 Loss, Beats Revenue Estimates
Ionis Pharmaceuticals (IONS) delivered earnings and revenue surprises of +46.96% and +21.23%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks
News Placeholder
Durect (DRRX) Reports Q2 Loss, Tops Revenue Estimates
Durect (DRRX) delivered earnings and revenue surprises of +46.15% and +39.69%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks
News Placeholder
electroCore, Inc. (ECOR) Reports Q2 Loss, Tops Revenue Estimates
electroCore (ECOR) delivered earnings and revenue surprises of -9.38% and +0.83%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks
News Placeholder
Amneal Pharmaceuticals (AMRX) Q2 Earnings Top Estimates
Amneal (AMRX) delivered earnings and revenue surprises of +38.89% and -0.15%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks
<
...
1
>

Advertisement|Remove ads.